Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Operating Margin (2021 - 2025)

Historic Operating Margin for Krystal Biotech (KRYS) over the last 4 years, with Q3 2025 value amounting to 42.3%.

  • Krystal Biotech's Operating Margin rose 155000.0% to 42.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.39%, marking a year-over-year increase of 310100.0%. This contributed to the annual value of 22.61% for FY2024, which is 2390400.0% up from last year.
  • Per Krystal Biotech's latest filing, its Operating Margin stood at 42.3% for Q3 2025, which was up 155000.0% from 40.93% recorded in Q2 2025.
  • Krystal Biotech's Operating Margin's 5-year high stood at 962.0% during Q1 2021, with a 5-year trough of 303.8% in Q3 2023.
  • Moreover, its 4-year median value for Operating Margin was 33.87% (2025), whereas its average is 85.95%.
  • Its Operating Margin has fluctuated over the past 5 years, first soared by 3306000bps in 2024, then surged by 155000bps in 2025.
  • Krystal Biotech's Operating Margin (Quarter) stood at 962.0% in 2021, then tumbled by -99bps to 7.45% in 2023, then surged by 509bps to 45.35% in 2024, then decreased by -7bps to 42.3% in 2025.
  • Its Operating Margin was 42.3% in Q3 2025, compared to 40.93% in Q2 2025 and 41.02% in Q1 2025.